Core Viewpoint - Medline's initial public offering (IPO) is set to be the largest of 2025, raising $6.26 billion and valuing the company at approximately $39 billion, despite a challenging economic environment for U.S. stock markets [12][13][14]. Company Overview - Medline is a medical supplies manufacturer based in Northfield, Illinois, founded in 1966 by brothers Jim and John Mills [2]. - The company produces around 335,000 different medical and surgical products, operating 33 global facilities and serving customers in over 100 countries [3]. Financial Performance - For the nine months ending September 27, Medline reported net sales of $20.6 billion and a net income of $977 million, compared to $18.7 billion in net sales and $911 million in net income for the same period the previous year [4]. IPO Details - Medline's IPO shares were priced at $29 each, at the higher end of the expected range of $26 to $30 [10]. - A total of 216,034,482 shares of Class A common stock were made available in the IPO [11]. - The IPO is expected to list on the Nasdaq Global Select Market under the ticker "MDLN" [9]. Historical Context - Medline has a history of public offerings, having originally gone public in 1972 before being taken private in 1977 [5]. - In 2021, a group of private equity investors acquired a majority stake in Medline for $34 billion, marking the largest leveraged buyout since the 2008 financial crisis [6]. Market Impact - Medline's IPO surpasses other significant IPOs in 2025, including the $5.3 billion raised by Contemporary Amperex Technology and the $1.75 billion raised by Venture Global [14].
Medline IPO: Stock price will be closely watched today as medical products company has biggest offering of 2025